Use of interleukin-2 in patients with acquired immunodeficiency syndrome

H. Clifford Lane; Jay P. Siegel; Alain H. Rook; Henry Masur; Edward P. Gelmann; Gerald V. Quinnan; Anthony S. Fauci

Use of interleukin-2 in patients with acquired immunodeficiency syndrome

H. Clifford Lane, Jay P. Siegel, Alain H. Rook, Henry Masur, Edward P. Gelmann, Gerald V. Quinnan, Anthony S. Fauci

Research output: Contribution to journal › Article › peer-review

Abstract

Twelve patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2. Doses ranged from 250 to 250,000 units. No clinical responses were seen. Minimal toxicity was noted and consisted of mild prolongation of partial thromboplastin time and proteinuria. Immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.

Original language	English (US)
Pages (from-to)	512-516
Number of pages	5
Journal	Journal of Biological Response Modifiers
Volume	3
Issue number	5
State	Published - Oct 1984
Externally published	Yes

Keywords

Acquired immunodeficiency syndrome
Immunomodulation
In vivo immune status
Interleukin-2
Toxicity

ASJC Scopus subject areas

Immunology
Pharmacology
Cancer Research

Cite this

@article{ee17a84710584a3caac9a49bb20ef70f,

title = "Use of interleukin-2 in patients with acquired immunodeficiency syndrome",

abstract = "Twelve patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2. Doses ranged from 250 to 250,000 units. No clinical responses were seen. Minimal toxicity was noted and consisted of mild prolongation of partial thromboplastin time and proteinuria. Immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.",

keywords = "Acquired immunodeficiency syndrome, Immunomodulation, In vivo immune status, Interleukin-2, Toxicity",

author = "Lane, {H. Clifford} and Siegel, {Jay P.} and Rook, {Alain H.} and Henry Masur and Gelmann, {Edward P.} and Quinnan, {Gerald V.} and Fauci, {Anthony S.}",

year = "1984",

month = oct,

language = "English (US)",

volume = "3",

pages = "512--516",

journal = "Journal of Biological Response Modifiers",

issn = "0732-6580",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Use of interleukin-2 in patients with acquired immunodeficiency syndrome

AU - Lane, H. Clifford

AU - Siegel, Jay P.

AU - Rook, Alain H.

AU - Masur, Henry

AU - Gelmann, Edward P.

AU - Quinnan, Gerald V.

AU - Fauci, Anthony S.

PY - 1984/10

Y1 - 1984/10

N2 - Twelve patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2. Doses ranged from 250 to 250,000 units. No clinical responses were seen. Minimal toxicity was noted and consisted of mild prolongation of partial thromboplastin time and proteinuria. Immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.

AB - Twelve patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2. Doses ranged from 250 to 250,000 units. No clinical responses were seen. Minimal toxicity was noted and consisted of mild prolongation of partial thromboplastin time and proteinuria. Immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.

KW - Acquired immunodeficiency syndrome

KW - Immunomodulation

KW - In vivo immune status

KW - Interleukin-2

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0021592103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021592103&partnerID=8YFLogxK

M3 - Article

C2 - 6334138

AN - SCOPUS:0021592103

SN - 0732-6580

VL - 3

SP - 512

EP - 516

JO - Journal of Biological Response Modifiers

JF - Journal of Biological Response Modifiers

IS - 5

ER -

Use of interleukin-2 in patients with acquired immunodeficiency syndrome

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this